Fennec Pharmaceuticals Inc.
FENC
Price:
$5.32
Market Cap:
$145.92M
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.[Read more]
Industry
Biotechnology
IPO Date
2017-09-15
Stock Exchange
NASDAQ
Ticker
FENC
PE Ratio
[-133.00]
ROE
[31.99%]
Current Ratio
[7.80]
Dividend Yield
[0%]
Enterprise Value
[105.60M]
Dividend History
The ROE as of November 2024 (TTM) for Fennec Pharmaceuticals Inc. (FENC) is 31.99%
According to Fennec Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current ROE is 31.99%. This represents a change of -86.81% compared to the average of 242.57% of the last 4 quarters.
Fennec Pharmaceuticals Inc. (FENC) Historical ROE (quarterly & annually)
How has FENC ROE performed in the past?
The mean historical ROE of Fennec Pharmaceuticals Inc. over the last ten years is 20.16%. The current 31.99% ROE has changed 58.68% with respect to the historical average. Over the past ten years (40 quarters), FENC's ROE was at its highest in in the March 2024 quarter at 426.35%. The ROE was at its lowest in in the September 2022 quarter at -291.22%.
Average
20.16%
Median
-69.89%
Minimum
-354.98%
Maximum
966.87%
Fennec Pharmaceuticals Inc. (FENC) ROE by Quarter and Year
Discovering the peaks and valleys of Fennec Pharmaceuticals Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 179.94%
Maximum Annual ROE = 966.87%
Minimum Annual Increase = -973.60%
Minimum Annual ROE = -354.98%
| Year | ROE | Change |
|---|---|---|
| 2023 | 138.06% | -85.72% |
| 2022 | 966.87% | -973.60% |
| 2021 | -110.68% | 79.52% |
| 2020 | -61.65% | -41.24% |
| 2019 | -104.93% | 126.16% |
| 2018 | -46.39% | 76.18% |
| 2017 | -26.33% | -66.29% |
| 2016 | -78.12% | -35.04% |
| 2015 | -120.26% | -66.12% |
| 2014 | -354.98% | 179.94% |
Fennec Pharmaceuticals Inc. (FENC) Average ROE
How has FENC ROE performed in the past?
The current ROE of Fennec Pharmaceuticals Inc. (FENC) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
331.42%
5-year avg
165.54%
10-year avg
20.16%
Fennec Pharmaceuticals Inc. (FENC) ROE vs. Peers
How is FENC’s ROE compared to its peers?
Fennec Pharmaceuticals Inc.’s ROE is greater than Molecular Partners AG (-39.16%), greater than MediciNova, Inc. (-20.70%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), less than Champions Oncology, Inc. (323.52%), greater than Cyteir Therapeutics, Inc. (-9.44%), greater than Keros Therapeutics, Inc. (-41.74%), greater than Janux Therapeutics, Inc. (-10.46%), greater than Edgewise Therapeutics, Inc. (-26.83%), less than Harmony Biosciences Holdings, Inc. (23.16%), less than Ikena Oncology, Inc. (0%), greater than Aerovate Therapeutics, Inc. (-39.59%), greater than Eliem Therapeutics, Inc. (-90.19%), greater than Decibel Therapeutics, Inc. (-47.03%), greater than Olema Pharmaceuticals, Inc. (-56.38%), greater than Disc Medicine, Inc. (-53.55%), greater than Larimar Therapeutics, Inc. (-25.24%), greater than Orchestra BioMed Holdings, Inc. (-35.87%), greater than null (-107.04%),
| Company | ROE | Market cap |
|---|---|---|
| -39.16% | $216.81M | |
| -20.70% | $104.47M | |
| -184.40% | $37.86M | |
| 323.52% | $61.85M | |
| -9.44% | $108.71M | |
| -41.74% | $2.27B | |
| -10.46% | $2.64B | |
| -26.83% | $3.05B | |
| 23.16% | $1.94B | |
| 0% | $82.52M | |
| -39.59% | $76.81M | |
| -90.19% | $342.68M | |
| -47.03% | $123.37M | |
| -56.38% | $503.07M | |
| -53.55% | $1.93B | |
| -25.24% | $393.05M | |
| -35.87% | $219.34M | |
| -107.04% | $0 |
Build a custom stock screener for Fennec Pharmaceuticals Inc. (FENC) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Fennec Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Fennec Pharmaceuticals Inc. (FENC) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Fennec Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Fennec Pharmaceuticals Inc.'s ROE?
How is the ROE calculated for Fennec Pharmaceuticals Inc. (FENC)?
What is the highest ROE for Fennec Pharmaceuticals Inc. (FENC)?
What is the 3-year average ROE for Fennec Pharmaceuticals Inc. (FENC)?
What is the 5-year average ROE for Fennec Pharmaceuticals Inc. (FENC)?
How does the current ROE for Fennec Pharmaceuticals Inc. (FENC) compare to its historical average?